Building Better Therapeutics
Amunix is an industry leader in the discovery and development of long-acting protein-based therapeutics. Amunix’ pipeline products are based on our proprietary XTEN® half-life extension, Antibody-XTEN-Drug Conjugate and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these technologies over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with leading biotechnology and pharma companies.